Milestone Pharmaceuticals MIST 深 滬
已收盤 05-08 16:00:00 美东时间
1.92
+0.030
+1.59%
華盛通- 最 高1.93
- 今 開1.90
- 成交量 60.22万股
- 最 低 1.875
- 昨 收 1.89
- 總市值 2.30亿
- 52周最高 3.06
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.00
- 委 比 -71.16%
- 總股本 1.20亿
- 歷史最高 27.95
- 量 比 0.55
- 振 幅 2.91%
- 歷史最低 0.6254
- 每 手 1
- 風險率 0.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals granted 123,000 stock options to three new employees under its 2021 Inducement Plan, with an exercise price of $1.31 per share. The options vest over four years, with 25% vesting after one year and the remainder vesting in monthly installments. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. Milestone is a biopharmaceutical company focused on developing cardiovascular medi...
04-02 12:00
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
Milestone Pharmaceuticals announced that Express Scripts has added CARDAMYST to its national formulary, making it accessible to commercially insured patients. CARDAMYST is the first FDA-approved nasal spray for acute PSVT episodes, improving access and affordability. The company expects further coverage expansion through additional payer collaborations.
03-31 12:00
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Azitra (AMEX:AZTR) stock rose 52.6% to $0.27 during Friday's regular s...
03-21 01:06
Why Milestone Pharma Stock Is Taking A Dive Today
EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, solid sales beat and cash runway into 2027.
03-20 23:40
Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last
03-20 19:26
Earnings Scheduled For March 20, 2026
Companies Reporting Before The Bell • BitFuFu (NASDAQ:FUFU) is likely to report...
03-20 19:11
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16 cents per share on $1.20M revenue.
03-20 14:23
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will report 4Q and full-year 2025 results and provide a business update on Friday, March 20, 2026, followed by a conference call and webcast at 8:30am ET. Participants can join via dial-in numbers (1-877-407-0792 for US, 1-201-689-8263 for international) using conference ID 13759195, or via the webcast link. A replay will be available on the company's website. Milestone is a biopharmaceutical company ...
03-12 12:00
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Milestone Pharmaceuticals Inc. has appointed David Sandoval as General Counsel and Chief Compliance Officer ahead of the launch of CARDAMYST™ (etripamil) nasal spray, the first FDA-approved self-administered treatment for PSVT episodes in adults. Sandoval brings over 15 years of experience in legal and compliance roles across the life sciences sector, with a focus on regulatory approval and commercialization. Joseph Oliveto, Milestone’s President...
02-10 13:00
